Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: The ALPHEE study
Interpretation of the results of the electrophysiologic study versus electrocardiographic monitoring (ESVEM) study: Programmed ventricular stimulation advocates' view
Mitchell LB, Wyse DG. Interpretation of the results of the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) study: programmed ventricular stimulation advocates view. Coron Artery Dis. 1994;5:671-676. (Pubitemid 24302190)
ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities
American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; Society of Thoracic Surgeons
Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA III, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; Society of Thoracic Surgeons. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm. 2008;5:e1-e62.
Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator
DOI 10.1161/01.CIR.0000149240.98971.A8
Dorian P, Borggrefe M, Al-Khalidi HR, Hohnloser SH, Brum JM, Tatla DS, Brachmann J, Myerburg RJ, Cannom DS, van der Laan M, Holroyde MJ, Singer I, Pratt CM; SHock Inhibition Evaluation with azimiLiDe (SHIELD) Investigators. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation. 2004;110: 3646-3654. (Pubitemid 39665252)
(2004)Circulation, vol.110, Issue.24, pp. 3646-3654
Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators
Van Herendael H, Pinter A, Ahmad K, Korley V, Mangat I, Dorian P. Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators. Europace. 2010;12:618-625.
Comparison of β-blockers, amiodarone plus β-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators - The OPTIC study: A randomized trial
DOI 10.1001/jama.295.2.165
Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K, Champagne J, Talajic M, Coutu B, Gronefeld GC, Hohnloser SH; Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295:165-171. (Pubitemid 43076435)
Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia
Van Herendael H, Dorian P. Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia. Vasc Health Risk Manag. 2010;6:465-472.
Prevention of implantable-defibrillator shocks by treatment with sotalol
DOI 10.1056/NEJM199906173402402
Pacifico A, Hohnloser SH, Williams JH, Tao B, Saksena S, Henry PD, Prystowsky EN; d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. Prevention of implantable-defibrillator shocks by treatment with sotalol. N Engl J Med. 1999;340:1855-1862. (Pubitemid 29272665)
In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: Electrophysiological, anti-adrenergic, and anti-angiotensin II effects
DOI 10.1097/00005344-200408000-00015
Gautier P, Guillemare E, Dijandjighian L, Marion A, Planchenault J, Bernhart C, Herbert JM, Nisato D. In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, antiadrenergic, and anti-angiotensin II effects. J Cardiovasc Pharmacol. 2004;44:244-257. (Pubitemid 38982169)
In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias
DOI 10.1097/01.fjc.0000151899.03379.76
Gautier P, Serre M, Cosnier-Pucheu S, Djandjighian L, Roccon A, Herbert JM, Nisato D. In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias. J Cardiovasc Pharmacol. 2005;45:125-135. (Pubitemid 40170675)
Placebo-controlled double-blind dose-ranging study of the efficacy and safety of SSR149744C in patients with recent atrial fibrillation/flutter
Abstract
Kowey PR, Aliot EM, Capucci A, Connolly SJ, Crijns HJ, Hohnloser SH, Kulakowski P, Roy D, Radzik D, Singh BN. Placebo-controlled double-blind dose-ranging study of the efficacy and safety of SSR149744C in patients with recent atrial fibrillation/flutter. Heart Rhythm. 2007;4:S72. Abstract.
Double blind placebo COntrolled Dose ranging study of the efficacy and safety of SSR149744c 300 or 600 mg for the conversion of atrial fibrillation/fluttEr (CORYFEE)
Accessed October 3, 2011
Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation/fluttEr (CORYFEE). Clinical Trials Web site. http://www. clinicaltrials.gov/ct2/show/NCT00232310?term-CORYFEE&rank-1. Accessed October 3, 2011.
Celivarone in patients with an implantable cardioverter-defibrillator (ICD): Adjunctive therapy for the reduction of ventricular arrhythmia-triggered ICD interventions
published online ahead of print Oct 3
Gojkovic O, Aliot EM, Capucci A, Connolly SJ, Crijns H, Hohnloser SH, Kulakowski P, Roy D, Radzik D, Singh BN, Kowey PR. Celivarone in patients with an implantable cardioverter-defibrillator (ICD): adjunctive therapy for the reduction of ventricular arrhythmia-triggered ICD interventions [published online ahead of print Oct 3, 2011]. Heart Rhythm.
Dronedarone for prevention of atrial fibrillation: A dose-ranging study
DOI 10.1016/S0195-668X(03)00321-X
Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24:1481-1487. (Pubitemid 37010577)